Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery.

Autor: Muñoz MPS; Bariatric and Metabolic Surgery Department, Nuevo Hospital Civil de Guadalajara 'Dr Juan I Menchaca', Guadalajara, Jalisco, Mexico., Blandón JDR; Nuevo Hospital Civil de Guadalajara 'Dr Juan I Menchaca', Guadalajara, Mexico. daniel_reyes205@hotmail.com., Gutierrez ISC; Nuevo Hospital Civil de Guadalajara 'Dr Juan I Menchaca', Guadalajara, Mexico., Mendoza CMM; Bariatric and Metabolic Surgery Department, Nuevo Hospital Civil de Guadalajara 'Dr Juan I Menchaca', Guadalajara, Jalisco, Mexico., Aguiñaga MSA; Bariatric and Metabolic Surgery Department, Nuevo Hospital Civil de Guadalajara 'Dr Juan I Menchaca', Guadalajara, Jalisco, Mexico., Orozco CAO; Nuevo Hospital Civil de Guadalajara 'Dr Juan I Menchaca', Guadalajara, Mexico.
Jazyk: angličtina
Zdroj: Updates in surgery [Updates Surg] 2024 Oct; Vol. 76 (6), pp. 2277-2283. Date of Electronic Publication: 2024 Apr 04.
DOI: 10.1007/s13304-024-01828-0
Abstrakt: Preoperative management of patients living with severe obesity can be challenging; in this context, the preoperative weight loss may help to obtain better outcomes and less morbidity for bariatric surgery. Therefore, we evaluated the effectiveness of GLP-1 analogue Liraglutide in preoperative weight loss. We performed a single-center, quasi-experimental prospective study. Eligible participants were adults in preoperative management for bariatric-metabolic surgery with body-mass index ≥ 48 kg/m 2 . All patients were assigned liraglutide treatment, with an initial dose of 0.6 mg subcutaneous per day, the dose was increased each week until reaching 3.0 mg for 12 weeks. Weight loss and body composition were evaluated monthly using bioelectric impedance (BIA) (InBody 770 Scale®). We analyzed data using descriptive statistics, central tendency measures and dispersion for quantitative variables and absolute and relative frequencies for qualitative variables. A total of 37 individuals were included in this study, 28 (76%) were female and 9 (24%) were males, with an average age of 44 years. About the BMI, 19 patients (51%) had a BMI > 50 kg/m 2 , 10 (27%) > 40 kg/m 2 and 8 (22%) > 60 kg/m 2 ; with a total average BMI of 56.04 kg/m 2 . The initial weight was 147.4 ± 14.9 kg which decreased to 139.3 ± 16.8 kg; after 3 months of liraglutide administration. A total of 35 patients had some degree of weight loss (94.6%), while 2 (5.40%) had no weight changes. The total weight loss was 5.50% at 3 months of liraglutide treatment. Liraglutide could be an effective adjuvant therapy for preoperative weight loss in patients living with severe obesity.
(© 2024. Italian Society of Surgery (SIC).)
Databáze: MEDLINE
Externí odkaz: